Genenta Welcomes New Directors John L. Cantello, Lauren H. Chung, Armon R. Sharei and Todd Wider

Article content

MILAN, Italy and NEW YORK, May 6, 2024 (GLOBE NEWSWIRE) — Genenta Science (NASDAQ: GNTA), a clinical-stage immuno-oncology company developing a cell-based platform that harnesses the power of hematopoietic stem cells to produce long-lasting and safe products to provide treatments for solid tumors, announces that its ordinary and extraordinary shareholders’ meeting was held on May 2, 2024. At the Annual and Special Shareholders’ Meeting, the Company’s shareholders voted to appoint five directors to the Company’s Board of Directors, effective May 2, 2024, including four new members. The new board members include: John L. Cantello, Ph.D., Lauren H. Chung, Ph.D., Armon R. Sharei, Ph.D. and Todd Wider, MD, And Pierluigi Paracchi, Chief Executive Officer will continue to serve as Chairman of the Board.

Article content

“When Luigi Naldini, Ph.D., MD, and I co-founded Genenta, we always sought to include leaders in the biotech industry. This board is fantastic. “Our new directors will help Genenta consolidate the important results we have achieved to date and expand the potential impact of our cell therapy to treat tumors,” he said Pierluigi Paracchi.

Article content

The Company thanks the former Board members for their significant contributions during their tenure.

John L. Cantello, Ph.D.
John is an independent consultant to the biopharmaceutical industry with over 20 years of experience. John was a former vice president and head of business development for oncology therapeutics at GlaxoSmithKline and vice president and head of BD, respiratory and immune diseases at AstraZeneca. John has led teams responsible for evaluating, evaluating and executing M&A, pipeline and commercial asset transactions in the areas of oncology, respiratory, inflammation, metabolism and rare diseases. He has a track record of closing deals (with a deal value of over $30 billion) in primary care, specialty care and rare diseases.

Article content

Article content

Lauren H. Chung, Ph.D.
Lauren has over 20 years of operational experience leading agile investment management strategies and tactical asset allocation in the healthcare industry. As founder and CEO of Minleigh LLC, a strategic consulting firm specializing in healthcare, Lauren has advised executives, boards of directors and investment firms on global strategic plans, M&A, integration and compliance. Previously, Lauren co-founded Tokum Capital Management, a global institutional healthcare fund, and successfully led its merger with Perella Weinberg Partners. Lauren serves on boards of public and private companies. She has a Ph.D. in Biomedical Sciences from Columbia University Vagelos College of Physicians and Surgeons, an MBA from Columbia Business School, and a BA in Biochemistry and Economics with honors from Wellesley College.

Armon R. Sharei, Ph.D.
Armon is the founder and CEO of Portal Bio and formerly the CEO and founder of SQZ Biotechnologies, where he led the company from invention to IPO with over $300 million in equity financing, a collaboration with Roche valued at $1 billion and led three clinical trials. He graduated from Stanford University and received his Ph.D. at the Massachusetts Institute of Technology and as a postdoctoral fellow at Harvard Medical School.

Article content

Todd Wider, MD
Todd has served as a consultant to numerous biotechnology companies. He is co-founder and board member of Xanadu Bio and former chairman of Emendo Biotetherapeutics, board member of Abeona Therapeutics and Arya Science Acquisition Corp IV (Nasdaq: ARYD). Todd is an active honorary member of the medical staff at Mount Sinai Hospital in New York City. He received his MD from Vagelos College of Physicians and Surgeons at Columbia University, where he was a Rudin Fellow, and an AB with honors and Phi Beta Kappa from Princeton University. Todd is also a principal actor at Wider Film Projects, a documentary film company focused on producing films with socio-political resonance that have won Oscars, Emmys and Peabody Awards.

Additional information relating to Genenta’s meeting of stockholders will be reported on a Form 6-K filed with the Securities and Exchange Commission and made available on the company’s website (www.genenta.com).

About Genenta and Temferon
Genenta (www.genenta.com) is a clinical-stage biotechnology company developing a proprietary hematopoietic stem cell therapy for the treatment of various solid tumor cancers. Temferon™ is based on ex vivo gene transfer into autologous Tie2+ hematopoietic stem/progenitor cells (HSPCs) to deliver immunomodulatory molecules directly via tumor-infiltrating monocytes/macrophages (Tie2-expressing monocytes – TEMs). Temferon, being studied in a Phase 1/2a clinical trial in newly diagnosed glioblastoma multiforme patients with an unmethylated MGMT gene promoter (uMGMT-GBM), is designed to reach solid tumors and induce a durable immune response that is not due to pre- This is one of the greatest unsolved challenges in immuno-oncology.

Article content

Forward-Looking Statements
Statements in this press release contain “forward-looking statements” within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 that are subject to significant risks and uncertainties. All statements contained in this press release, other than statements of historical fact, are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as “expect,” “believe,” “contemplate,” “could,” “estimate,” “anticipate,” “intend,” “seek,” “may,” “could”, “plan”, “potential”, “predict”, “project”, “suggest”, “aim”, “aim”, “should”, “will”, “would” or the negative of these words or others similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on Genenta’s current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict, including risks associated with the completion and timing of the Phase 1/2a clinical trial or any trials for the treatment of patients with glioblastoma multiforme that have an unmethylated MGMT gene promoter (uMGMT-GBM). In addition, certain forward-looking statements are based on assumptions about future events that may not prove to be accurate. These and other risks and uncertainties are described in more detail in the “Risk Factors” section of Genenta’s Annual Report on Form 20-F for the year ended December 31, 2022, filed with the Securities and Exchange Commission. The forward-looking statements contained in this release are made as of the date hereof and Genenta undertakes no obligation to update this information, except as required by applicable law.

Genenta Media: Tiziana Pollio, mobile +39 348 23 15 143 [email protected]

Article content